Identifying a pathway to improve outcomes for men with high-risk localised and metastatic hormone sensitive prostate cancer.
Movember is partnering with the ICECaP Consortium to leverage the natural alignment of our shared goal to accelerate global progress on a strategic approach that can significantly reduce the number of men dying from prostate cancer.
Please join us in this fourth webinar for an update on the progress from five ICECaP working groups.
TUESDAY MAY 14TH 2024
Pacific Daylight Time (PDT) > 1PM – 3PM
Eastern Daylight Time (EDT) > 4PM – 6PM
British Summer Time (BST) > 9PM – 11PM
Central European Standard Time (CEST) > 10PM – 12AM
WEDNESDAY MAY 15TH 2024
Australian Eastern Standard Time (AEST) > 6AM – 8AM
Webinar link will be provided with confirmation of registration.
ABOUT MOVEMBER
Movember is the leading charity changing the face of men’s health. Since 2003, Movember has invested over AUD $600m to fund more than 1,000 prostate cancer projects spanning biomedical research, clinical trials, clinical quality registries and survivorship programs. A key objective for Movember is to help reduce the number of men progressing to advanced disease through early detection and optimal treatment of men diagnosed with clinically significant disease. Movember is proud to support the ICECaP Consortium to reduce the number of men dying from prostate cancer.
ABOUT ICECaP
The ICECaP initiative commenced in 2013 with ‘start-up’ funding from The Prostate Cancer Foundation, to identify early clinical endpoints as surrogates for overall survival for adjuvant clinical trials. Based on this work, “Metastasis-free survival” is now widely used as a primary endpoint to expedite adjuvant therapy trials. The International ICECaP collaboration has brought together medical and radiation oncologists, urologists, health economists, statisticians, biologists and patient representatives. This collaboration has allowed the scope of the program to expand and also include biological, quality of life and health economic analyses.